A phase III study comparing carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L CBDCA/PEM vs DOC Phase III)

Trial Profile

A phase III study comparing carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L CBDCA/PEM vs DOC Phase III)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Pemetrexed (Primary) ; Carboplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CBDCA/PEM-vs-DOC-Phase III
  • Most Recent Events

    • 21 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Aug 2015 Planned number of patients changed from 320 to 430 as reported by University Hospital Medical Information Network - Japan.
    • 13 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top